A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of BI 655130 Induction Therapy in patients with moderate-to-severely active ulcerative colitis who have failed previous biologics therapy
Phase of Trial: Phase II/III
Latest Information Update: 09 Jan 2019
At a glance
- Drugs Spesolimab (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
- 09 Jul 2018 Planned End Date changed from 30 Nov 2020 to 30 Jan 2021.
- 09 Jul 2018 Planned primary completion date changed from 22 Sep 2020 to 22 Nov 2020.
- 04 Apr 2018 Status changed from not yet recruiting to recruiting.